Meeting
2019 ASCO Annual Meeting
Real-world data analysis of ovarian cancer (OC) maintenance utilization among maintenance eligible patients.
Authors
David Garofalo
Integra Connect, West Palm Beach, FL
David Garofalo , Ebru Aydin , Monica Labrador , Jennifer Webster , Greg Brown , Joseph Donaldson , Hinco Jasper Gierman , Prateesh Varughese , Ash Malik , Jeffrey A. Scott
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5579)
DOI
10.1200/JCO.2019.37.15_suppl.5579
Abstract #
5579
Poster Bd #
402
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice.
First Author: Debra L. Richardson
First Author: Naomi N. Adjei
Poster
2022 ASCO Annual Meeting
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
First Author: JUNG-YUN LEE
Poster
2019 ASCO Annual Meeting
Recurrence of ovarian cancer in BRCAwt patients without maintenance therapy: Real-world evidence.
First Author: Melinda Louie-Gao